Clinical advances and ongoing trials on mRNA vaccines for cancer treatment

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. / Lorentzen, Cathrine Lund; Haanen, John B.; Met, Özcan; Svane, Inge Marie.

I: The Lancet Oncology, Bind 23, Nr. 10, 2022, s. e450-e458.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Lorentzen, CL, Haanen, JB, Met, Ö & Svane, IM 2022, 'Clinical advances and ongoing trials on mRNA vaccines for cancer treatment', The Lancet Oncology, bind 23, nr. 10, s. e450-e458. https://doi.org/10.1016/S1470-2045(22)00372-2

APA

Lorentzen, C. L., Haanen, J. B., Met, Ö., & Svane, I. M. (2022). Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. The Lancet Oncology, 23(10), e450-e458. https://doi.org/10.1016/S1470-2045(22)00372-2

Vancouver

Lorentzen CL, Haanen JB, Met Ö, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. The Lancet Oncology. 2022;23(10):e450-e458. https://doi.org/10.1016/S1470-2045(22)00372-2

Author

Lorentzen, Cathrine Lund ; Haanen, John B. ; Met, Özcan ; Svane, Inge Marie. / Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. I: The Lancet Oncology. 2022 ; Bind 23, Nr. 10. s. e450-e458.

Bibtex

@article{11278d0bf31c4dd0a33e1826199a4c9f,
title = "Clinical advances and ongoing trials on mRNA vaccines for cancer treatment",
abstract = "Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production, which rivals the best available conventional vaccine manufacture methods, renders mRNA vaccines a promising option for cancer immunotherapy. Technological advances have optimised mRNA-based vaccine stability, structure, and delivery methods, and multiple clinical trials investigating mRNA vaccine therapy are now enrolling patients with various cancer diagnoses. Although therapeutic mRNA-based cancer vaccines have not yet been approved for standard treatment, encouraging results from early clinical trials with mRNA vaccines as monotherapy and in combination with checkpoint inhibitors have been obtained. This Review summarises the latest clinical advances in mRNA-based vaccines for cancer treatment and reflects on future perspectives and challenges for this new and promising treatment approach.",
author = "Lorentzen, {Cathrine Lund} and Haanen, {John B.} and {\"O}zcan Met and Svane, {Inge Marie}",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",
year = "2022",
doi = "10.1016/S1470-2045(22)00372-2",
language = "English",
volume = "23",
pages = "e450--e458",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "TheLancet Publishing Group",
number = "10",

}

RIS

TY - JOUR

T1 - Clinical advances and ongoing trials on mRNA vaccines for cancer treatment

AU - Lorentzen, Cathrine Lund

AU - Haanen, John B.

AU - Met, Özcan

AU - Svane, Inge Marie

N1 - Publisher Copyright: © 2022 Elsevier Ltd

PY - 2022

Y1 - 2022

N2 - Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production, which rivals the best available conventional vaccine manufacture methods, renders mRNA vaccines a promising option for cancer immunotherapy. Technological advances have optimised mRNA-based vaccine stability, structure, and delivery methods, and multiple clinical trials investigating mRNA vaccine therapy are now enrolling patients with various cancer diagnoses. Although therapeutic mRNA-based cancer vaccines have not yet been approved for standard treatment, encouraging results from early clinical trials with mRNA vaccines as monotherapy and in combination with checkpoint inhibitors have been obtained. This Review summarises the latest clinical advances in mRNA-based vaccines for cancer treatment and reflects on future perspectives and challenges for this new and promising treatment approach.

AB - Years of research exploring mRNA vaccines for cancer treatment in preclinical and clinical trials have set the stage for the rapid development of mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and the inherent advantage in ease of production, which rivals the best available conventional vaccine manufacture methods, renders mRNA vaccines a promising option for cancer immunotherapy. Technological advances have optimised mRNA-based vaccine stability, structure, and delivery methods, and multiple clinical trials investigating mRNA vaccine therapy are now enrolling patients with various cancer diagnoses. Although therapeutic mRNA-based cancer vaccines have not yet been approved for standard treatment, encouraging results from early clinical trials with mRNA vaccines as monotherapy and in combination with checkpoint inhibitors have been obtained. This Review summarises the latest clinical advances in mRNA-based vaccines for cancer treatment and reflects on future perspectives and challenges for this new and promising treatment approach.

U2 - 10.1016/S1470-2045(22)00372-2

DO - 10.1016/S1470-2045(22)00372-2

M3 - Review

C2 - 36174631

AN - SCOPUS:85138797781

VL - 23

SP - e450-e458

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -

ID: 331362022